These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 11325808)

  • 1. Enhancement of the effects of a complete inhibitor of enkephalin-catabolizing enzymes, RB 101, by a cholecystokinin-B receptor antagonist in diabetic rats.
    Coudoré-Civiale MA; Méen M; Fournié-Zaluski MC; Boucher M; Roques BP; Eschalier A
    Br J Pharmacol; 2001 May; 133(1):179-85. PubMed ID: 11325808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins.
    Valverde O; Maldonado R; Fournie-Zaluski MC; Roques BP
    J Pharmacol Exp Ther; 1994 Jul; 270(1):77-88. PubMed ID: 8035345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A selective CCKB receptor antagonist potentiates, mu-, but not delta-opioid receptor-mediated antinociception in the formalin test.
    Noble F; Blommaert A; Fournié-Zaluski MC; Roques BP
    Eur J Pharmacol; 1995 Jan; 273(1-2):145-51. PubMed ID: 7737308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antinociceptive effects of RB101, a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by a cholecystokinin type B receptor antagonist, as revealed by noxiously evoked spinal c-Fos expression in rats.
    Honore P; Buritova J; Fournié-Zaluski MC; Roques BP; Besson JM
    J Pharmacol Exp Ther; 1997 Apr; 281(1):208-17. PubMed ID: 9103499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCKB antagonist PD-134,308.
    Maldonado R; Valverde O; Ducos B; Blommaert AG; Fournie-Zaluski MC; Roques BP
    Br J Pharmacol; 1995 Mar; 114(5):1031-9. PubMed ID: 7780637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCK-B receptors in the limbic system modulate the antidepressant-like effects induced by endogenous enkephalins.
    Smadja C; Ruiz F; Coric P; Fournié-Zaluski MC; Roques BP; Maldonado R
    Psychopharmacology (Berl); 1997 Aug; 132(3):227-36. PubMed ID: 9292622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weak tolerance to the antinociceptive effect induced by the association of a peptidase inhibitor and a CCKB receptor antagonist.
    Valverde O; Blommaert AG; Fournié-Zaluski MC; Roques BP; Maldonado R
    Eur J Pharmacol; 1995 Nov; 286(1):79-93. PubMed ID: 8566154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pain management by a new series of dual inhibitors of enkephalin degrading enzymes: long lasting antinociceptive properties and potentiation by CCK2 antagonist or methadone.
    Le Guen S; Mas Nieto M; Canestrelli C; Chen H; Fournié-Zaluski MC; Cupo A; Maldonado R; Roques BP; Noble F
    Pain; 2003 Jul; 104(1-2):139-48. PubMed ID: 12855323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of endogenous cholecystokinin in the facilitation of mu-mediated antinociception by delta-opioid agonists.
    Noble F; Smadja C; Roques BP
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1127-34. PubMed ID: 7996417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CI 988, an antagonist of the cholecystokinin-B receptor, potentiates endogenous opioid-mediated antinociception at spinal level.
    Xu XJ; Elfvin A; Hao JX; Fournié-Zaluski MC; Roques BP; Wiesenfeld-Hallin Z
    Neuropeptides; 1997 Jun; 31(3):287-91. PubMed ID: 9243527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spinal effect of the cholecystokinin-B receptor antagonist CI-988 on hyperalgesia, allodynia and morphine-induced analgesia in diabetic and mononeuropathic rats.
    Coudoré-Civiale MA; Courteix C; Fialip J; Boucher M; Eschalier A
    Pain; 2000 Oct; 88(1):15-22. PubMed ID: 11098095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats.
    Noble F; Soleilhac JM; Soroca-Lucas E; Turcaud S; Fournie-Zaluski MC; Roques BP
    J Pharmacol Exp Ther; 1992 Apr; 261(1):181-90. PubMed ID: 1560364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of the peptidase inhibitor RB 101 and a CCK-B antagonist strongly enhances antinociceptive responses.
    Maldonado R; Derrien M; Noble F; Roques BP
    Neuroreport; 1993 Jul; 4(7):947-50. PubMed ID: 8369487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidepressant-like effects of CCK(B) receptor antagonists: involvement of the opioid system.
    Hernando F; Fuentes JA; Fournié-Zaluski MC; Roques BP; Ruiz-Gayo M
    Eur J Pharmacol; 1996 Dec; 318(2-3):221-9. PubMed ID: 9016909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similar decrease in spontaneous morphine abstinence by methadone and RB 101, an inhibitor of enkephalin catabolism.
    Ruiz F; Fournié-Zaluski MC; Roques BP; Maldonado R
    Br J Pharmacol; 1996 Sep; 119(1):174-82. PubMed ID: 8872371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of tolerance to the antinociceptive effects of systemic morphine by a selective cholecystokinin-B receptor antagonist in a rat model of peripheral neuropathy.
    Idänpään-Heikkilä JJ; Guilbaud G; Kayser V
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1366-72. PubMed ID: 9316848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of morphine and clomipramine analgesia by cholecystokinin -B antagonist CI-988 in diabetic rats.
    Coudoré-Civiale MA; Courteix C; Boucher M; Méen M; Fialip J; Eschalier A; Ardid D
    Neurosci Lett; 2000 May; 286(1):37-40. PubMed ID: 10822147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In mononeuropathic rats, the enhancement of morphine antinociception by L-365,260, a selective CCK(B) receptor antagonist, depends on the dose of systemic morphine and stimulus characteristics.
    Idänpään-Heikkilä JJ; Perrot S; Guilbaud G; Kayser V
    Eur J Pharmacol; 1997 May; 325(2-3):155-64. PubMed ID: 9163562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antinociceptive effects of RB101(S), a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by (+)-HA966, a functional NMDA receptor antagonist: a c-Fos study in the rat spinal cord.
    Buritova J; Le Guen S; Fournié-Zaluski MC; Roques BP; Besson JM
    Eur J Pain; 2003; 7(3):241-9. PubMed ID: 12725847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiological control of emotion-related behaviors by endogenous enkephalins involves essentially the delta opioid receptors.
    Nieto MM; Guen SL; Kieffer BL; Roques BP; Noble F
    Neuroscience; 2005; 135(2):305-13. PubMed ID: 16112476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.